High prevalence of aspirin resistance in elderly patients with cardiovascular disease and metabolic syndrome

Background Metabolic syndrome is known to be a prothrombotic state. We undertook this study to examine a hypothesis that aspirin resistance may be associated with metabolic syndrome, and to assess other potential determinants of aspirin resistance in patients with cardiovascular disease （CVD）. Methods A total of 469 elderly patients with CVD were recruited. One hundred and seventy-two patients with metabolic syndrome and 297 without metabolic syndrome （control group） received daily aspirin therapy （〉 75 mg） over one month. Platelet aggregation was measured by light transmission aggregometry （LTA）. Aspirin resistance was defined as 〉 20% arachidonic acid （AA）- and 〉 70% adenosine diphosphate （ADP）-induced aggregation according to LTA. Aspirin semi-responders were defined as meeting one （but not both） of these criteria. Results By LTA, 38 of 469 （8.1%） patients were aspirin resistant. The prevalence of aspirin resistance was higher in the metabolic syndrome group compared with the control group [11.6 % vs. 6.6%, odds ratio （OR） = 2.039; 95% confidence interval （CI）： 1.047-3.973]. In the multivariate logistic regression analysis, metabolic syndrome （OR = 4.951, 95% CI： 1.440-17.019, P = 0.011） was a significant risk factor for aspirin resistance. Conclusions A significant number of patients with CVD and metabolic syndrome are resistant to aspirin therapy. This might further increase the risk of cardiovascular morbidity and mortality in these patients.

Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease

Background Resistance to anti-platelet therapy is detrimental to patients. Our aim was to establish a predictive model for aspirin resistance to identify high-risk patients and to propose appropriate intervention. Methods Elderly patients （n = 1130） with stable chronic coronary heart disease who were taking aspirin （75 mg） for 〉 2 months were included. Details of their basic characteristics, laboratory test results, and medications were collected. Logistic regression analysis was performed to establish a predictive model for aspirin resistance. Risk score was finally established according to coefficient B and type of variables in logistic regression. The Hosmer-Lemeshow （HL） test and receiver operating characteristic curves were performed to respectively test the calibration and discrimination of the model. Results Seven risk factors were included in our risk score. They were serum creatinine （〉 110 μmol/L, score of 1）; fasting blood glucose （〉 7.0 mmol/L, score of 1）; hyperlipidemia （score of 1）; number of coronary arteries （2 branches, score of 2; 〉 3 branches, score of 4）; body mass index （20-25 kg/m2, score of 2; 〉 25 kg/m2, score of 4）; percutaneous coronary intervention （score of 2）; and smoking （score of 3）. The HL test showed P ≥ 0.05 and area under the receiver operating characteristic curve ≥ 0.70. Conclusions We explored and quantified the risk factors for aspirin resistance. Our predictive model showed good calibration and discriminative power and therefore a good foundation for the further study of patients undergoing anti-platelet therapy.

Clinical importance of aspirin and clopidogrel resistance

Aspirin and clopidogrel are important components of medical therapy for patients with acute coronary syndromes, for those who received coronary artery stents and in the secondary prevention of ischaemic stroke. Despite their use, a significant number of patients experience recurrent adverse ischaemic events. Interindividual variability of platelet aggregation in response to these antiplatelet agents may be an explanation for some of these recurrent events, and small trials have linked "aspirin and/or clopidogrel resistance", as measured by platelet function tests, to adverse events. We systematically reviewed all available evidence on the prevalence of aspirin/clopidogrel resistance, their possible risk factors and their association with clinical outcomes. We also identified articles showing possible treatments. After analyzing the data on different laboratory methods, we found that aspirin/clopidogrel resistance seems to be associated with poor clinical outcomes and there is currently no standardized or widely accepted definition of clopidogrel resistance. Therefore, we conclude that specific treatment recommendations are not established for patients who exhibit high platelet reactivity during aspirin/clopidogrel therapy or who have poor platelet inhibition by clopidogrel.

Aspirin resistance: Fact or fiction? A point of view

Aspirin is a wonder drug that has been used for well over 100 years for its analgesic and antipyretic effects. For the past three decades, it has increasingly been used for the prevention of primary and secondary cardiovascular events. Lately, it has been suggested that a significant number of individuals taking aspirin have become resistant to this drug. The phenomenon of "aspirin resistance" is based on the observation of clinical events in some patients taking aspirin, and/or a diminished platelet aggregation inhibitory response to aspirin therapy. Unfortunately, laboratory assays used to monitor the efficacy of aspirin are far from accurate and the results are not reproducible. Furthermore, results of different platelet function tests are often not congruent. In addition, platelet aggregation studies show marked interindividual and intra-individual variability. Patients with coronary heart disease take many drugs that interfere with the effect of aspirin on platelet aggregation. Besides inhibiting formation of thromboxane A2 from arachidonic acid, aspirin has a host of platelet-independent effects that complement its platelet inhibitory effects. Laboratory assays designed to measure platelet function do not take into account these pleiotropic effects of aspirin. In our view, use of the term "aspirin resistance" based on inadequate knowledge of imperfect laboratory tests does a disservice to physicians and patients.

Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery

We sought to assess the incidence of aspirin resistance after off-pump coronary artery bypass （OPCAB） surgery, and investigate whether clopidogrel can improve aspirin response and be safely applied early after OPCAB surgery. Sixty patients who underwent standard OPCAB surgery were randomized into two groups. One group （30 patients） received mono-antiplatelet treatment （MAPT） with aspirin 100 mg daily and the other group received dual anfiplatelet treatment （DAPT） with aspirin 100 mg daily plus clopidogrel 75 mg daily. Platelet aggregations in response to arachi- donic acid （PLAA） and adenosine diphosphate （ADP） （PLADP） were measured preoperatively and on days 1 to 6, 8 and 10 after the antiplatelet agents were administered. A PLAA level above 20% was defined as aspirin resistance. Postoperative bleeding and other perioperative variables were also recorded. There were no significant differences between the two groups in baseline characteristics, average number of distal anastomosis, operation time, postoperative bleeding, ventilation time and postoperative hospital stay. However, the incidence of aspirin resistance was significantly lower in the DAPT group than that in the MAPT group on the first and second day after antiplatelet agents were given （62.1% vs, 32.1%, 34.5% vs. 10.7%, respectively, both P 〈 0.05）. There was no significant difference in postoperative complication between the two groups. DAPT with aspirin and clopidogrel can be safely applied to OPCAB patients early after the procedure. Moreover, clopidogrel reduces the incidence of OPCAB-related aspirin resistance.

Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentrations of antimicrobials

AIM： To investigate the increasing the susceptibility pylon） to metronidazole. mechanisms of aspirin of Helicobacter pylori （H METHODS： Hpylori reference strain 26695 and two metronidazole-resistant isolates of H pylori were included in this study. Strains were incubated in Brucella broth with or without aspirin （1 mmol/L）. The rdxA gene of Hpylori was amplified by PCR and sequenced. The permeability of Hpylori to antimicrobials was determined by analyzing the endocellular radioactivity of the cells after incubated with [7-^3H]-tetracycline. The outer membrane proteins （OMPs） of Hpylori 26695 were depurated and analyzed by SDS-PAGE. The expression of 5 porins （hopA, hopB, hopC, hopD and hopE） and the putative RND efflux system （hefABC） of H pylori were analyzed using real-time quantitative PCR. RESULTS： The mutations in rdxA gene did not change in metronidazole resistant isolates treated with aspirin. The radioactivity of H pylori increased when treated with aspirin, indicating that aspirin improved the permeability of the outer membrane of H pylori. However, the expression of two OMP bands between 55 kDa and 72 kDa altered in the presence of aspirin.The expression of the mRNA of hopA, hopB, hopC, hopD, hopE and herA, hefB, hefC of H pylori did not change when treated with aspirin. CONCLUSION： Although aspirin increases the susceptibility of H pylori to metronidazole, it has no effect on the mutations of rdxA gene of Hpylori. Aspirin increases endocellular concentrations of antimicrobials probably by altering the OMP expression.

Association of the Platelet Membrane Glycoprotein Ⅰa C807T Gene Polymorphism with Aspirin Resistance

To explore the correlation between the C807T polymorphism of platelet membrane glycoprotein Ⅰa （GP Ⅰa） gene and aspirin resistance in Chinese people, 200 patients with high-risk of atherosclerosis took aspirin （100 mg/d） for 7 days. Platelet aggregation function was detected using adenosine diphosphate （ADP） and arachidonic acid （AA） before and after the administration of aspirin. Then the subjects were divided into three groups according to the results of platelet aggregation function： an aspirin resistant （AR） group, an aspirin semi-responder （ASR） group and an aspirin-sensitive （AS） group. Platelet GP Ⅰa gene 807CT polymorphism was examined by means of polymerase chain reaction-sequence specific primers （PCR-SSP）. The results showed that T allelic frequency in AR group and ASR group were higher that of AS group （P〈0.005）, and the prevalence of genotypes （TT＋TC） of these two groups was significantly higher than that in AS group （P〈0.05）. Platelet GP Ⅰa T allele was significantly associated with aspirin resistance as revealed by multiple logistic regression （OR=3.76, 95% CI： 2.87-9.58）. The results suggest that inherited platelet GP Ⅰa variations may have an important impact on aspirin resistance and the presence of GP Ⅰa T allele may be a marker of genetic susceptibility to aspirin resistance.

Profile and prevalence of aspirin resistance in patients with metabolic syndrome

Objective Aspirin has been used extensively in primary and secondary prevention of cardiovascular disease,particularly for subjects at high risk such as metabolic syndrome.However,the responsiveness to aspirin treatment may vary among individuals.The present study was conducted to investigate the profile and prevalence of aspirin resistance in patients with metabolic syndrome.Methods In 221 consecutive patients,platelet aggregation induced by arachidonic acid (0.5mg/ml) was assessed after 10 days of aspirin treatment (200mg/d).Aspirin resistance was defined as mean optical platelet aggregation =20%.Results Aspirin resistance occurred in 39 patients (17.6%).Serum fibrinogen level was higher in patients with than in those without aspirin resistance (2.6_+0.4g/l vs 2.4±0.4g/L,P=0.017).The 2 groups,aspirin resistance group and no aspirin resistance group,did not differ significantly,with regard to gender,age,body mass index,waist-hip ratio,blood pressure level,serum cholesterol level and history of myocardial or cerebral infarction.Multivariate logistic regression analysis revealed that only serum fibrinogen level entered the model (odds ratio 2.973,p=0.023).Subgroup analysis further showed that aspirin resistance occurred more in male patients with myocardial infarction (50% vs14.5%,P=0.02) and in female patients with diastolic blood pressure=85mmHg (34% vs 15.5%,P=0.043).But after multifactor logistic regression,in women blood pressure=85mmHg was not a predictor any more.Conclusions In patients with metabolic syndrome,aspirin resistance is not uncommon,especially for men with history of myocardial infarction.Patients with aspirin resistance have an increased serum fibrinogen level.(J Geriatr Cardio12008;5:7-10)

Aspirin resistance in young men with Type 2 diabetes

Objective: Aspirin resistance (AR) or poor response to aspirin is said to be high among subjects with diabetes and more so in patients with poor glycemic control. The aim of our study was to evaluate the prevalence of AR among subjects with diabetes with moderate glycemic control and its association with inflammatory markers and cytokines. Design: This is a single-center open-label prospective clinical study. Methods: The study included 142 young male veterans (mean age of 49years) with Type 2 diabetes, with HbA1C of 7.7 ± 1.1. Urinary 11-dehydro-thromboxane beta-2 (11DhTx2) concentrations measured by immunoassay are the primary outcome measures. Results: Urinary 11DhTxB2 levels ≥ 1500 pg/mg of creatinine is considered as AR. Approximately 53% of subjects had AR. There are no significant differences in the clinical parameters, such as age, history of hypertension or BMI, waist to hip ratio;as well as biochemical parameters, such as HbA1C, lipid parameters or serum creatinine, between subjects with or without AR. Levels of 11DhTxB2 /cre correlated with history of CAD, abdominal fat content and IL-6 levels (p < 0.01) as well as abdominal fat content and IL-6 levels;duration of diabetes and history of CAD. Conclusions: Aspirin resistance is common in subjects with diabetes even with moderate control. Additional measures to improve aspirin response should be considered. Further studies with larger groups are needed to clarify the AR with various associated risk factors.

Clinical Intervention Effect of Compound Danshen Dripping Pills on Aspirin Resistant Patients with Coronary Heart Disease

[Objectives]To study the clinical intervention effect of Compound Danshen Dripping Pills on aspirin-resistant patients with coronary heart disease(CHD).[Methods]240 patients with coronary heart disease who took Aspirin were selected to measure thrombocytopenia by sonoclot.They were randomly divided into four groups:group A(n=60),Compound Danshen Dripping Pills and aspirin.group B(n=60),aspirin;group C(n=60),high dose aspirin;group D(n=60),Compound Danshen Dripping Pills.CR and PF were determined by sonoclot after one month.The incidence of angina pectoris,acute myocardial infarction,sudden cardiac death and hemorrhage were observed.[Results]After treatment,the CR and PF levels of group A and C were significantly lower than those before treatment,and there was no significant difference between group B and D and before treatment.After treatment,the levels of CR and PF in group A and C were significantly lower than those in group B and D,and there was a significant difference.Angina pectoris and myocardial infarction events in group D were significantly higher than the other four groups;hemorrhage events in group C were significantly higher than the other three groups.[Conclusions]Compound Danshen Dripping Pills combined with aspirin can be used as an economical,effective,and more dependent alternative to inhibit platelet activity in aspirin resistance,and can further reduce the occurrence of acute coronary events.

Study on Related Factors of Aspirin Resistance in Acute Ischemic Stroke

Objective:To study the related factors of aspirin resistance(AR)in acute ischemic stroke.Methods:A total of 138 patients with acute ischemic stroke treated in hospital affiliated to Xuzhou medical university from August 2016 to August 2018 were the study subjects,examine his medical data from the past.They were divided into the AR group(40 cases)and the non-AR group(98 cases)according to whether AR appears.Gender,disease history,biochemical indicators and etc.were compared between the two groups.The independent risk factors of AR were investigated using univariate analysis and logistic regression analysis.Results:40 cases of AR occurred in 138 patients,with an incidence rate of 28.99%.Diabetes,platelet count(PLT),microRNA-19a(m iR-19a)expression,smoking,high-sensitivity C-reactive protein(hs-CRP),Low-density lipoprotein cholesterol(LDL-C),fibrinogen(FIB)and age difference between the AR group and non-AR group was statistically significant(P<0.05).Gender,hypertension,uric acid(UA),high-density lipoprotein cholesterol(HDL-C),triglycerides(TG),homocysteine(Hcy),total cholesterol(TC),and alanine aminotransferase(ALT)between the two groups were not significantly different(P>0.05).Logistic regression analysis showed that the independent risk factors for AR in acute ischemic stroke were diabetes(OR=2.773,95%CI:1.102~5.065,P=0.025),miR-19a(OR=3.021,95%CI:1.322~6.545,P=0.021),hs-CRP(OR=2.719,95%CI:1.301~5.022,P=0.028)and smoking(OR=1.983,95%CI:1.114~3.887,P=0.040).Conclusion:The incidence of AR is higher in acute ischemic stroke.Risk factors include diabetes,miR-19a expression,hs-CRP,smoking,etc.Clinical intervention measures can be taken to reduce the risk of AR and improve acute ischemic stroke prognosis.

阿司匹林抵抗和脂蛋白相关磷脂酶A2与复发性缺血性脑卒中的相关性分析

目的探讨非心源性卒中患者阿司匹林抵抗和脂蛋白相关磷脂酶A2(Lp-PLA2)与缺血性脑卒中复发的相关性。方法选取2021-10—2022-10在永城市人民医院住院的发病7 d内的急性非心源性缺血性脑卒中患者72例,基于临床病史和神经影像学证据分为初发组(n=36)和复发组(n=36),入院后规律服用阿司匹林7 d。采用血栓弹力图测定阿司匹林抵抗,并测定血清Lp-PLA2水平。比较初发组和复发组阿司匹林抵抗、Lp-PLA2水平,分析阿司匹林抵抗、Lp-PLA2与缺血性脑卒中复发之间的相关性。采用多元Logistic回归分析筛选复发性卒中独立危险因素,ROC曲线下面积评价相关危险因素的预测价值。结果36.1%的复发性卒中患者存在阿司匹林抵抗,19.4%的初发患者存在阿司匹林抵抗,2组比较差异有统计学意义(P<0.001)。复发性卒中患者血清PLA2水平中位数160.0μg/L,初次发病患者为125.0μg/L,2组比较差异有统计学意义(P=0.008)。多元Logistic回归分析显示阿司匹林抵抗和高PLA2水平是复发性缺血性脑卒中的影响因素,阿司匹林抵抗患者卒中复发风险增加4.06倍(P=0.042),高于Lp-PLA2中位值患者的4.37倍(P=0.011)。阿司匹林抵抗和Lp-PLA2预测卒中复发的ROC曲线下面积分别为0.753(95%CI:0.641~0.873)和0.683(95%CI:0.559~0.807)。结论与初发卒中患者相比,复发性卒中患者阿司匹林抵抗的比率和血清Lp-PLA2水平均明显升高,可作为复发性卒中的预测因素。

在U表面循环Ar^+轰击-磁控溅射离子镀Al层

用循环Ar+ 轰击 -磁控溅射离子镀 (MSIP)法在U表面上镀Al,并采用俄歇电子能谱仪 (SAM )、扫描电镜(SEM)、电化学实验和湿热腐蚀加速实验 ,研究了其表面、剖面形貌和耐蚀性能 ,以及U基和Al镀层界面 .结果表明 :U上循环Ar+ 轰击 -磁控溅射离子镀Al界面存在较宽的原子共混区 。

U表面循环Ar^+轰击-磁控溅射离子镀Ti研究

用设计的循环Ar+轰击-磁控溅射离子镀法在U表面上镀Ti,并采用扫描电镜(SEM)、X射线光电子能谱仪和湿热加速腐蚀实验,研究了其表面、剖面形貌、镀层的组成与结构、膜基界面特征,以及耐湿热腐蚀性能。结果表明,U上循环Ar+轰击-磁控溅射离子镀Ti层结晶致密、晶粒细化,镀层由表及里分别由TiO2/TiO/Ti构成,镀层厚度≥4μm时、其试样的耐湿热腐蚀性能较之金属U来讲有较大程度的提高。

冠脉粥样硬化患者AR中医证型分布及活血胶囊对血瘀型AR的干预作用

目的明确阿司匹林抵抗与冠状动脉粥样硬化患者中医证型的关系以及中药活血胶囊对阿司匹林抵抗血瘀型患者的影响,为有效降低阿司匹林抵抗发生率提供预测和治疗新思路。方法对冠状动脉粥样硬化需服用阿司匹林的310例患者通过专家商讨确定其所属中医证型,随访两年;并在临床研究前后测定血小板聚集率。将发生阿司匹林抵抗血瘀型的37例患者随机分成三组,空白对照组(13例)、活血胶囊治疗组(12例)、活血胶囊联合阿司匹林组(12例)。用以研究活血胶囊改善阿司匹林抵抗的作用。结果心血瘀阻型发生阿司匹林抵抗(28.5%)明显高于寒凝心脉型(10.0%)、痰浊内阻型(16.7%)、心气虚弱型(15.9%)、心肾阴虚型(15.0%)和心肾阳虚型(20.0%),经χ2检验差异有统计学意义(P<0.05)。心血瘀阻型患者服用活血胶囊3个月可降低血小板聚集率,但与空白组比较差异无统计学意义;而活血胶囊联合阿司匹林治疗明显降低血小板聚集率,与空白组比较差异有统计学意义(P<0.05)。结论心血瘀阻型患者更易发生阿司匹林抵抗;活血化瘀方药活血胶囊具有降低血小板聚集的作用,联合应用阿司匹林能够明显降低阿司匹林抵抗的发生。

VerifyNow-Aspirin评估阿司匹林抗血小板效应及其影响因素分析

目的联合VerifyNow-Aspirin与尿11-脱氢-血栓烷B2测定,评估阿司匹林抗血小板效应及其影响因素。方法选择规律服用阿司匹林至少两周的冠心病患者264例,年龄33～86(65.31±10.23)岁,其中男147例(55.7%),女117例(44.3%)。阿司匹林标准剂量组(100mg/d)241例,低剂量组(25～75mg/d)23例。采用VerifyNow-aspirin系统测定服用阿司匹林后血小板残余活性(用ARU表示),酶联免疫吸附法检测尿11-脱氢-血栓烷B2(11-DH-TXB2)浓度,并记录入选人群的基线资料及心血管疾病危险因素。结果以ARU≥550为切割值定义阿司匹林低反应性(ALR)人群,标准剂量组人群中ALR发生率为8.6%(23例)。ALR人群尿11-DH-TXB2显著高于正常反应组,差异有统计学意义(2.85±0.73pg/ml vs 2.51±0.49pg/ml,P<0.05),但二者之间相关性较差(r=0.18,P=0.04)。女性、高血压及糖尿病均为ARU升高的预测因素(均P<0.05),但其组间尿11-DH-TXB2水平差异无统计学意义(均P>0.05)。与阿司匹林标准剂量组比较,低剂量组人群残余血小板活性显著增强,同时伴有尿11-DH-TXB2升高(均P<0.05)。结论阿司匹林抗血小板效应存在个体差异,且具有一定量效关系,而VerifyNow和尿11-DH-TXB2对评估阿司匹林抗血小板效应及其发生机制具有一定互补性。

Ar^+激光器用于电阻微调的研究

本文讨论并研究了Ａｒ＋激光器用于电阻微调的优越性。结果表明，在比常用的Ｎｄ∶ＹＡＧ激光功率小得多的情况下。

脑梗死患者PEAR1、PTGS1基因交互作用与阿司匹林抵抗的相关性分析

目的探讨脑梗死患者血小板内皮聚集受体-1(PEAR1)和前列腺素内过氧化物合酶-1(PTGS1)基因交互作用与阿司匹林抵抗的相关性,为脑梗死患者抗血小板个体化治疗提供参考.方法选取经头部核磁共振(MRI)平扫或计算机断层扫描(CT)平扫证实为脑梗死的患者100例为研究对象,入院后记录患者一般资料和既往病史,所有患者均满足阿司匹林100 mg/d单抗治疗.应用荧光染色原位杂交法检测基因分型,酶联免疫吸附(ELISA)法测定尿液中11-脱氢-血栓烷B2(11-DH-TXB2)含量.依据11-DH-TXB2含量将患者分为阿司匹林抵抗组(Aspirin resistance,AR)和阿司匹林敏感组(Aspirin sensitivity,AS).结果一般资料中性别、体质量指数(BMI)和高血压、糖尿病、吸烟、饮酒史、PEAR1基因多态性在两组间差异均无统计学意义(P>0.05).PTGS1基因型、GG基因型比例阿司匹林抵抗组高于敏感组,差异具有统计学意义(P<0.001).多因素分析结果显示:PTGS1基因多态性是阿司匹林抵抗的影响因素,GG基因型发生阿司匹林抵抗的概率是A G/AA基因型的24.489倍(95%CI 4.910~122.150).PEAR1与PTGS1两基因型交互作用分析显示:PTGS1基因型为GG且PEAR1基因型为AG/AA时,OR值增加,两基因对阿司匹林抵抗的发生存在交互作用(API=17.628%).结论PEAR1基因多态性与阿司匹林抵抗无明显相关性;PTGS1基因GG型是阿司匹林抵抗的独立危险因素;PTGS1基因型为GG且PEAR1基因型为AG/AA时存在交互作用,可增加患者阿司匹林抵抗风险.

2型糖尿病人群胰岛素抵抗和β_3-AR基因的相关性

目的探讨β3肾上腺素能受体基因与2型糖尿病胰岛素抵抗的关系。方法对131例糖尿病患者和40例正常对照者,应用PCR-RFLP技术扩增β3-AR基因,抽血测定空腹血糖、总胆固醇、甘油三酯、高密度脂蛋白胆固醇,糖化血红蛋白、胰岛素。结果2型糖尿病与正常人群β3-AR基因型和等位基因频率没有差异,但在2型糖尿病组,携带β3-AR基因64位Arg突变的患者,其胰岛素抵抗指数(HOMA-IR)显著高于无突变组(P<0.05)。结论β3-AR基因多态与2型糖尿病胰岛素抵抗有相关性。

Ar^+注入对大豆幼苗抗旱性的影响

主根长、侧根数目、根冠比、叶绿素含量等是幼苗耐旱的重要特征。为研究干旱胁迫条件下,不同Ar+注入剂量对大豆幼苗抗旱性指标的影响,利用能量为25 ke V,剂量分别为0(对照),500,1 000,1 500,2 000,2 500,3 000,3 500,4 000×2.6×1013ions·cm-2的Ar+注入大豆干种子。结果表明,剂量为1 500×2.6×1013ions·cm-2的Ar+能有效促进大豆幼苗生长,一定剂量的Ar+注入能促进主根伸长,增加侧根数,增大根冠比,提高叶绿素、脯氨酸含量和过氧化物酶活性。